Literature DB >> 19351161

The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.

Sarah M Drawz1, Christopher R Bethel, Kristine M Hujer, Kelly N Hurless, Anne M Distler, Emilia Caselli, Fabio Prati, Robert A Bonomo.   

Abstract

Inhibitor-resistant class A beta-lactamases of the TEM and SHV families that arise by single amino acid substitutions are a significant threat to the efficacy of beta-lactam/beta-lactamase inhibitor combinations. To better understand the basis of the inhibitor-resistant phenotype in SHV, we performed mutagenesis to examine the role of a second-shell residue, Asn276. Of the 19 variants expressed in Escherichia coli, only the Asn276Asp enzyme demonstrated reduced susceptibility to ampicillin/clavulanate (MIC increased from 50/2 --> 50/8 microg/mL) while maintaining high-level resistance to ampicillin (MIC = 8192 microg/mL). Steady-state kinetic analyses of Asn276Asp revealed slightly diminished k(cat)/K(m) for all substrates tested. In contrast, we observed a 5-fold increase in K(i) for clavulanate (7.4 +/- 0.9 microM for Asn276Asp vs 1.4 +/- 0.2 microM for SHV-1) and a 40% reduction in k(inact)/K(I) (0.013 +/- 0.002 microM(-1 )s(-1) for Asn276Asp vs 0.021 +/- 0.004 microM(-1) s(-1) for SHV-1). Timed electrospray ionization mass spectrometry of clavulanate-inhibited SHV-1 and SHV Asn276Asp showed nearly identical mass adducts, arguing for a similar pathway of inactivation. Molecular modeling shows that novel electrostatic interactions are formed between Arg244Neta2 and both 276AspOdelta1 and Odelta2; these new forces restrict the spatial position of Arg244, a residue important in the recognition of the C(3)/C(4) carboxylate of beta-lactam substrates and inhibitors. Testing the functional consequences of this interaction, we noted considerable free energy costs (+DeltaDeltaG) for substrates and inhibitors. A rigid carbapenem (meropenem) was most affected by the Asn276Asp substitution (46-fold increase in K(i) vs SHV-1). We conclude that residue 276 is an important second-shell residue in class A beta-lactamase-mediated resistance to substrates and inhibitors, and only Asn is able to precisely modulate the conformational flexibility of Arg244 required for successful evolution in nature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351161      PMCID: PMC4030617          DOI: 10.1021/bi9003292

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  46 in total

1.  The structural bases of antibiotic resistance in the clinically derived mutant beta-lactamases TEM-30, TEM-32, and TEM-34.

Authors:  Xiaojun Wang; George Minasov; Brian K Shoichet
Journal:  J Biol Chem       Date:  2002-06-10       Impact factor: 5.157

Review 2.  Beta-lactamases: a survey of protein diversity.

Authors:  Marion S Helfand; Robert A Bonomo
Journal:  Curr Drug Targets Infect Disord       Date:  2003-03

Review 3.  The discovery and development of modified penicillin- and cephalosporin-derived beta-lactamase inhibitors.

Authors:  John D Buynak
Journal:  Curr Med Chem       Date:  2004-07       Impact factor: 4.530

4.  Antibody mapping of the linear epitopes of CMY-2 and SHV-1 beta-lactamases.

Authors:  Andrea M Hujer; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.

Authors:  Jodi M Thomson; Fabio Prati; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

6.  Automated analysis of enzyme inactivation phenomena. Application to beta-lactamases and DD-peptidases.

Authors:  F De Meester; B Joris; G Reckinger; C Bellefroid-Bourguignon; J M Frère; S G Waley
Journal:  Biochem Pharmacol       Date:  1987-07-15       Impact factor: 5.858

7.  Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors.

Authors:  Aranapakam M Venkatesan; Atul Agarwal; Takao Abe; Hideki Ushirogochi; Itsuki Yamamura; Toshio Kumagai; Peter J Petersen; William J Weiss; Eileen Lenoy; Youjun Yang; David M Shlaes; John L Ryan; Tarek S Mansour
Journal:  Bioorg Med Chem       Date:  2004-11-15       Impact factor: 3.641

8.  Beta-lactamase inhibitors. The inhibition of serine beta-lactamases by specific boronic acids.

Authors:  I E Crompton; B K Cuthbert; G Lowe; S G Waley
Journal:  Biochem J       Date:  1988-04-15       Impact factor: 3.857

9.  Inhibition of class A and class C beta-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate.

Authors:  Michiyoshi Nukaga; Takao Abe; Aranapakam M Venkatesan; Tarek S Mansour; Robert A Bonomo; James R Knox
Journal:  Biochemistry       Date:  2003-11-18       Impact factor: 3.162

10.  Nanomolar inhibitors of AmpC beta-lactamase.

Authors:  Federica Morandi; Emilia Caselli; Stefania Morandi; Pamela J Focia; Jesús Blázquez; Brian K Shoichet; Fabio Prati
Journal:  J Am Chem Soc       Date:  2003-01-22       Impact factor: 15.419

View more
  18 in total

1.  A combined molecular dynamics and rapid kinetics approach to identify conserved three-dimensional communication networks in elongation factor Tu.

Authors:  Hans-Joachim Wieden; Evan Mercier; John Gray; Brett Steed; Davis Yawney
Journal:  Biophys J       Date:  2010-12-01       Impact factor: 4.033

2.  SHV-129: A Gateway to Global Suppressors in the SHV β-Lactamase Family?

Authors:  Marisa L Winkler; Robert A Bonomo
Journal:  Mol Biol Evol       Date:  2015-11-03       Impact factor: 16.240

3.  Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.

Authors:  Krisztina M Papp-Wallace; Marisa L Winkler; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

4.  Evolution of the genetic code by incorporation of amino acids that improved or changed protein function.

Authors:  Brian R Francis
Journal:  J Mol Evol       Date:  2013-06-07       Impact factor: 2.395

5.  Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors.

Authors:  Wei Ke; Jared M Sampson; Claudia Ori; Fabio Prati; Sarah M Drawz; Christopher R Bethel; Robert A Bonomo; Focco van den Akker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

6.  Analysis of the binding forces driving the tight interactions between beta-lactamase inhibitory protein-II (BLIP-II) and class A beta-lactamases.

Authors:  Nicholas G Brown; Dar-Chone Chow; Banumathi Sankaran; Peter Zwart; B V Venkataram Prasad; Timothy Palzkill
Journal:  J Biol Chem       Date:  2011-07-20       Impact factor: 5.157

7.  Avibactam and inhibitor-resistant SHV β-lactamases.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

8.  N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.

Authors:  Marion J Skalweit; Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

9.  Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.

Authors:  Marisa L Winkler; Elizabeth A Rodkey; Magdalena A Taracila; Sarah M Drawz; Christopher R Bethel; Krisztina M Papp-Wallace; Kerri M Smith; Yan Xu; Jeffrey R Dwulit-Smith; Chiara Romagnoli; Emilia Caselli; Fabio Prati; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2013-02-04       Impact factor: 7.446

10.  Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.

Authors:  Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton; Marion J Skalweit
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.